Mobile

A phase II, controlled, randomized, single centre, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine with various doses of AS03 adjuvant co...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-003769-15

A phase II, controlled, randomized, single centre, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine with various doses of AS03 adjuvant compared to Fluarix™ (GlaxoSmithKline Biologicals) administered intramuscularly in subjects aged 18-59 years old

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the humoral immune response (anti-haemagglutinin antibody titres) elicited by the low dose influenza vaccine adjuvanted with AS03 (full or half dose of AS03) and by Fluarix given intramuscularly in subjects aged 18-59 years old, 21 days following vaccination.

Critère d'inclusion

  • Immunization against influenza in male and female subjects aged 18-59 years old

Liens